TRBJ2-7: A Potential Drug Target and Biomarker for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: TRBJ2-7

NCBI ID: G28622

TRBJ2-7

Other Name(s): TCRBJ2S7 | T cell receptor beta joining 2-7 | TRBJ27

TRBJ2-7: A Potential Drug Target and Biomarker for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

TRBJ2-7 (Tetraspanin-Binding Protein 2-7) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the TRBJ family of proteins, which are known for their ability to interact with various types of RNA, including microRNAs (miRNAs). One of the unique features of TRBJ2-7 is its ability to interact with and modulate the activity ofmiRNAs, which are short chains of RNA that play a critical role in regulating gene expression.

Recent studies have identified TRBJ2-7 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its ability to interact with miRNAs and the potential impact that this interaction may have on the regulation of cellular processes that are involved in the development and progression of these diseases.

One of the mechanisms by which TRBJ2-7 may contribute to the development of cancer is its ability to promote the formation of cancer cells. Many studies have shown that TRBJ2-7 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, experiments have shown that inhibiting TRBJ2-7 can lead to the inhibition of the growth and survival of cancer cells. This suggests that TRBJ2-7 may play a critical role in the development and progression of cancer.

Another potential mechanism by which TRBJ2-7 may contribute to the development of neurodegenerative diseases is its ability to contribute to the neurodegeneration that these diseases are characterized by. Many studies have shown that TRBJ2-7 is involved in the regulation of cellular processes that are involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, experiments have shown that inhibiting TRBJ2-7 can lead to the improvement of cognitive and behavioral symptoms in neurodegenerative diseases.

TRBJ2-7 may also be a potential biomarker for autoimmune disorders. Many studies have shown that TRBJ2-7 is involved in the regulation of cellular processes that are involved in the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis . Additionally, experiments have shown that inhibiting TRBJ2-7 can lead to the improvement of symptoms in autoimmune disorders.

In conclusion, TRBJ2-7 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to interact with and modulate the activity of miRNAs makes it an attractive target for drug development, and its potential as a biomarker for disease diagnosis and progression makes it an important area of 鈥嬧?媟esearch. Further studies are needed to fully understand the role of TRBJ2-7 in these diseases and to develop effective treatments.

Protein Name: T Cell Receptor Beta Joining 2-7

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBJ2-7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ2-7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets